[
  {
    "ts": null,
    "headline": "CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?",
    "summary": "CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.",
    "url": "https://finnhub.io/api/news?id=80e91f10b910bf0a4c9b52a5eac8b15b7722faeffb1530fc27a57548314eaea2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750860180,
      "headline": "CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?",
      "id": 135527467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.",
      "url": "https://finnhub.io/api/news?id=80e91f10b910bf0a4c9b52a5eac8b15b7722faeffb1530fc27a57548314eaea2"
    }
  }
]